Abbott to obtain Visiogen, Expanding Vision Care Portfolio Abbott has announced a definitive contract to acquire Visiogen, Inc. For $400 million in cash, providing the business with a next-generation accommodating intraocular lens technology to address presbyopia for cataract sufferers. Visiogen, a held firm based in Irvine privately, Calif viagra ., with European functions in Karlsruhe, Germany, is an ophthalmic medical gadget company focusing on the development of fresh vision alternatives for patients with cataracts.
The outcomes from the placebo-controlled, phase 3 trials demonstrated statistically significant %ages of scientific remission per Mayo score at eight and 52 weeks in HUMIRA-treated patients in comparison to placebo. The security results were consistent with the known safety profile of HUMIRA no new safety signals were observed.e., corticosteroids, azathioprine, or 6-mercaptopurine). Mayo score is a way of measuring disease activity that ranges from 0 to 12 and includes stool rate of recurrence, anal bleeding, endoscopic findings and physician’s global assessment. Patients had been randomized to treatment with HUMIRA 160/80 mg , HUMIRA 80/40 mg or placebo.